PMID- 8766874
OWN - NLM
STAT- MEDLINE
DCOM- 19961002
LR  - 20061115
IS  - 0031-0808 (Print)
IS  - 0031-0808 (Linking)
VI  - 38
IP  - 1
DP  - 1996 Mar
TI  - Evaluation of low molecular weight heparin during and after aortic and carotid 
      surgery: dose finding study.
PG  - 15-21
AB  - Forty-four patients undergoing abdominal aortic surgery and twenty-eight patients 
      undergoing carotid surgery were randomly treated with different anticoagulant 
      regimens. During surgery, an unfractionated heparin (UFH) intravenous bolus of 50 
      IU/kg was compared with a low molecular weight heparin (LMWH) bolus of either 120 
      IU/kg, 80 IU/kg, 40 IU/kg or 20 IU/kg. Six hours after surgery and for 48 hours, 
      an UFH infusion was compared with an LMWH infusion of either 10,000 IU/day or 
      6,000 IU/day and then, a single LMWH subcutaneous injection of 3,075 IU was 
      administered. Heparin activity was measured by factor Xa inhibitor and by 
      prolongation of APTT which were studied 15, 30 and 60 minutes after 
      cross-clamping, at the end of surgery and six hours later, and on days 1, 2, 3 
      and 6. After a descriptive analysis of clinical and pharmacokinetic profiles of 
      each regimen, optimal LMWH treatment is proposed.
FAU - Alimi, Y S
AU  - Alimi YS
AD  - Department of Vascular Surgery, Hopital Nord, Chemin des Bourrelly, Marseille, 
      France.
FAU - Juhan, C
AU  - Juhan C
FAU - Barthelemy, P
AU  - Barthelemy P
FAU - Boudier, J L
AU  - Boudier JL
FAU - Pansart, M
AU  - Pansart M
FAU - Boutin, B
AU  - Boutin B
FAU - De Moro, S
AU  - De Moro S
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Italy
TA  - Panminerva Med
JT  - Panminerva medica
JID - 0421110
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Aged
MH  - Anticoagulants/*therapeutic use
MH  - Aorta, Abdominal/*surgery
MH  - Carotid Arteries/*surgery
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
EDAT- 1996/03/01 00:00
MHDA- 1996/03/01 00:01
CRDT- 1996/03/01 00:00
PHST- 1996/03/01 00:00 [pubmed]
PHST- 1996/03/01 00:01 [medline]
PHST- 1996/03/01 00:00 [entrez]
PST - ppublish
SO  - Panminerva Med. 1996 Mar;38(1):15-21.